{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:12Z","timestamp":1787003112640,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The study was funded by Insitut Pasteur du Cambodge seed funds."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01030-8","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:02:15Z","timestamp":1732708935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of one year immunity following rabies post-exposure prophylaxis in dog bite cases"],"prefix":"10.1038","volume":"9","author":[{"given":"Nisa","family":"Ya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Auerswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sothy","family":"Touch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraden","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanvannak","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisey","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotheary","family":"Sann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borita","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanthy","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veasna","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yik Sing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowath","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke","family":"Cantaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"1030_CR1","unstructured":"World Health Organization. WHO Expert Consultation on Rabies: Third Report. (World Health Organization, Geneva, 2018)."},{"key":"1030_CR2","unstructured":"Rabies. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies."},{"key":"1030_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.20506\/rst.37.2.2808","volume":"37","author":"AT Gilbert","year":"2018","unstructured":"Gilbert, A. T. Rabies virus vectors and reservoir species. Rev. Sci. Tech. Int. Off. Epizoot 37, 371\u2013384 (2018).","journal-title":"Rev. Sci. Tech. Int. Off. Epizoot"},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1371\/journal.pntd.0000511","volume":"3","author":"S Ly","year":"2009","unstructured":"Ly, S. et al. Rabies situation in Cambodia. PLoS Negl. Trop. Dis. 3, e511 (2009).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1030_CR5","doi-asserted-by":"publisher","first-page":"e0254192","DOI":"10.1371\/journal.pone.0254192","volume":"16","author":"V Chevalier","year":"2021","unstructured":"Chevalier, V. et al. Large scale dog population demography, dog management and bite risk factors analysis: a crucial step towards rabies control in Cambodia. PLoS ONE 16, e0254192 (2021).","journal-title":"PLoS ONE"},{"key":"1030_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2022.10.046","volume":"126","author":"H Gan","year":"2023","unstructured":"Gan, H. et al. Global burden of rabies in 204 countries and territories, from 1990 to 2019: results from the Global Burden of Disease Study 2019. Int. J. Infect. Dis. 126, 136\u2013144 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","volume":"36","author":"World Health Organization","year":"2018","unstructured":"World Health Organization null. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine 36, 5500\u20135503 (2018).","journal-title":"Vaccine"},{"key":"1030_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1473-3099(19)30311-1","volume":"19","author":"T Cantaert","year":"2019","unstructured":"Cantaert, T. et al. A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study. Lancet Infect. Dis. 19, 1355\u20131362 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1030_CR9","doi-asserted-by":"publisher","first-page":"197883","DOI":"10.1016\/j.virusres.2020.197883","volume":"278","author":"A Gholami","year":"2020","unstructured":"Gholami, A. et al. Seroconversion after three doses of intramuscular rabies vaccine as a post-exposure treatment. Virus Res. 278, 197883 (2020).","journal-title":"Virus Res."},{"key":"1030_CR10","unstructured":"World Health Organization. WHO Expert Committee on Biological Standardization: fifty-sixth report. (2007)."},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","volume":"71","author":"AK Rao","year":"2022","unstructured":"Rao, A. K. et al. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices\u2014United States, 2022. Morb. Mortal. Wkly. Rep. 71, 619\u2013627 (2022).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1128\/JVI.72.5.3711-3719.1998","volume":"72","author":"DC Hooper","year":"1998","unstructured":"Hooper, D. C. et al. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J. Virol. 72, 3711\u20133719 (1998).","journal-title":"J. Virol."},{"key":"1030_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002375","volume":"7","author":"CW Gnanadurai","year":"2013","unstructured":"Gnanadurai, C. W. et al. Presence of virus neutralizing antibodies in cerebral spinal fluid correlates with non-lethal rabies in dogs. PLoS Negl. Trop. Dis. 7, e2375 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1030_CR14","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.vaccine.2006.01.051","volume":"24","author":"P Khawplod","year":"2006","unstructured":"Khawplod, P. et al. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 24, 3084\u20133086 (2006).","journal-title":"Vaccine"},{"key":"1030_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1006\/clin.1994.1088","volume":"71","author":"O Thraenhart","year":"1994","unstructured":"Thraenhart, O. et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin. Immunol. Immunopathol. 71, 287\u2013292 (1994).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"1030_CR16","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/infdis\/jiab034","volume":"226","author":"CA De Pijper","year":"2022","unstructured":"De Pijper, C. A. et al. Long-term memory response after a single intramuscular rabies booster vaccination 10-24 years after primary immunization. J. Infect. Dis. 226, 1052\u20131056 (2022).","journal-title":"J. Infect. Dis."},{"key":"1030_CR17","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1080\/21645515.2021.1906601","volume":"17","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Long-term immunity and the effect of one or two booster doses with a lyophilized human rabies vaccine (human diploid cells) at 10 years post primary vaccination in China. Hum. Vaccines Immunother. 17, 3162\u20133168 (2021).","journal-title":"Hum. Vaccines Immunother."},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.virol.2014.10.025","volume":"0","author":"DA Barkhouse","year":"2015","unstructured":"Barkhouse, D. A., Faber, M. & Hooper, D. C. Pre- and post-exposure safety and efficacy of attenuated rabies virus vaccines are enhanced by their expression of IFN\u03b3. Virology 0, 174\u2013180 (2015).","journal-title":"Virology"},{"key":"1030_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/JVI.01572-14","volume":"89","author":"DA Barkhouse","year":"2015","unstructured":"Barkhouse, D. A. et al. Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon. J. Virol. 89, 312\u2013322 (2015).","journal-title":"J. Virol."},{"key":"1030_CR20","first-page":"239","volume":"289","author":"M Lafon","year":"2005","unstructured":"Lafon, M. Modulation of the immune response in the nervous system by rabies virus. Curr. Top. Microbiol. Immunol. 289, 239\u2013258 (2005).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1030_CR21","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s00705-017-3484-0","volume":"162","author":"ISS Katz","year":"2017","unstructured":"Katz, I. S. S., Guedes, F., Fernandes, E. R. & Dos Ramos Silva, S. Immunological aspects of rabies: a literature review. Arch. Virol. 162, 3251\u20133268 (2017).","journal-title":"Arch. Virol."},{"key":"1030_CR22","first-page":"7666","volume":"176","author":"TW Phares","year":"2006","unstructured":"Phares, T. W., Kean, R. B., Mikheeva, T. & Hooper, D. C. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. Baltim. Md. 176, 7666\u20137675 (2006).","journal-title":"J. Immunol. Baltim. Md."},{"key":"1030_CR23","first-page":"7334","volume":"178","author":"TW Phares","year":"2007","unstructured":"Phares, T. W., Fabis, M. J., Brimer, C. M., Kean, R. B. & Hooper, D. C. A peroxynitrite-dependent pathway is responsible for blood-brain barrier permeability changes during a central nervous system inflammatory response: TNF-alpha is neither necessary nor sufficient. J. Immunol. Baltim. Md. 178, 7334\u20137343 (2007).","journal-title":"J. Immunol. Baltim. Md."},{"key":"1030_CR24","doi-asserted-by":"publisher","first-page":"10694","DOI":"10.18632\/oncotarget.7428","volume":"7","author":"CW Gnanadurai","year":"2016","unstructured":"Gnanadurai, C. W. & Fu, Z. F. CXCL10 and blood-brain barrier modulation in rabies virus infection. Oncotarget 7, 10694\u201310695 (2016).","journal-title":"Oncotarget"},{"key":"1030_CR25","doi-asserted-by":"publisher","first-page":"e25414","DOI":"10.1371\/journal.pone.0025414","volume":"6","author":"H Wang","year":"2011","unstructured":"Wang, H. et al. Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus. PLOS ONE 6, e25414 (2011).","journal-title":"PLOS ONE"},{"key":"1030_CR26","first-page":"691","volume":"14","author":"DC Hooper","year":"2000","unstructured":"Hooper, D. C. et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 14, 691\u2013698 (2000).","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/vaccines7030110","volume":"7","author":"LA Overduin","year":"2019","unstructured":"Overduin, L. A., van Dongen, J. J. M. & Visser, L. G. The cellular immune response to rabies vaccination: a systematic review. Vaccines 7, 110 (2019).","journal-title":"Vaccines"},{"key":"1030_CR28","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1016\/j.vaccine.2009.07.093","volume":"27","author":"H Wilde","year":"2009","unstructured":"Wilde, H., Khawplod, P. & Hemachudha, T. Post-exposure rabies prophylaxis in patients with AIDS. Vaccine 27, 5726\u20135727 (2009).","journal-title":"Vaccine"},{"key":"1030_CR29","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1086\/324087","volume":"33","author":"T Tantawichien","year":"2001","unstructured":"Tantawichien, T., Jaijaroensup, W., Khawplod, P. & Sitprija, V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 33, E122\u2013E124 (2001).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/003655401750174183","volume":"33","author":"C Pancharoen","year":"2001","unstructured":"Pancharoen, C. et al. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand. J. Infect. Dis. 33, 390\u2013391 (2001).","journal-title":"Scand. J. Infect. Dis."},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2249.1991.tb05709.x","volume":"85","author":"M Herzog","year":"1991","unstructured":"Herzog, M. et al. T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination. Clin. Exp. Immunol. 85, 224\u2013230 (1991).","journal-title":"Clin. Exp. Immunol."},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.vaccine.2016.12.031","volume":"35","author":"L Wijaya","year":"2017","unstructured":"Wijaya, L. et al. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers. Vaccine 35, 1175\u20131183 (2017).","journal-title":"Vaccine"},{"key":"1030_CR33","doi-asserted-by":"publisher","unstructured":"Auerswald, H. et al. Side-by-side comparative study of the immunogenicity of the intramuscular and intradermal rabies post-exposure prophylaxis regimens in a cohort of suspected RABV exposed individuals. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. ciad304 https:\/\/doi.org\/10.1093\/cid\/ciad304 (2023).","DOI":"10.1093\/cid\/ciad304"},{"key":"1030_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.7774\/cevr.2015.4.1.68","volume":"4","author":"MM Venkataswamy","year":"2015","unstructured":"Venkataswamy, M. M. et al. Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes. Clin. Exp. Vaccine Res. 4, 68\u201374 (2015).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"1030_CR35","unstructured":"World Organisation for Animal Health. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. in Chapter 3.1.18. Rabies (Infection with Rabies Virus and Other Lyssaviruses) (WOAH, 2023)."},{"key":"1030_CR36","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1586\/14760584.2014.971764","volume":"13","author":"T Tantawichien","year":"2014","unstructured":"Tantawichien, T. et al. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis. Expert Rev. Vaccines 13, 1593\u20131601 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2009.09.090","volume":"28","author":"DH Ashwathnarayana","year":"2009","unstructured":"Ashwathnarayana, D. H. et al. A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab). Vaccine 28, 148\u2013151 (2009).","journal-title":"Vaccine"},{"key":"1030_CR38","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1016\/j.vaccine.2019.07.055","volume":"37","author":"P Janewongwirot","year":"2019","unstructured":"Janewongwirot, P. et al. A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children. Vaccine 37, 5307\u20135313 (2019).","journal-title":"Vaccine"},{"key":"1030_CR39","first-page":"61","volume":"16","author":"U Bijok","year":"1984","unstructured":"Bijok, U. et al. Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. J. Commun. Dis. 16, 61\u201369 (1984).","journal-title":"J. Commun. Dis."},{"key":"1030_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/INF.0b013e3181906351","volume":"28","author":"K Pengsaa","year":"2009","unstructured":"Pengsaa, K. et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr. Infect. Dis. J. 28, 335\u2013337 (2009).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1030_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4161\/hv.7.2.14003","volume":"7","author":"H Liu","year":"2011","unstructured":"Liu, H. et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum. Vaccin. 7, 220\u2013224 (2011).","journal-title":"Hum. Vaccin."},{"key":"1030_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.prevetmed.2015.11.018","volume":"123","author":"K Tojinbara","year":"2016","unstructured":"Tojinbara, K. et al. Estimating the probability distribution of the incubation period for rabies using data from the 1948-1954 rabies epidemic in Tokyo. Prev. Vet. Med. 123, 102\u2013105 (2016).","journal-title":"Prev. Vet. Med."},{"key":"1030_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e00998","volume":"23","author":"M Shengli","year":"2021","unstructured":"Shengli, M. et al. A case of human rabies with a long incubation period in Wuhan. IDCases 23, e00998 (2021).","journal-title":"IDCases"},{"key":"1030_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-12-387040-7.00004-4","volume":"79","author":"DC Hooper","year":"2011","unstructured":"Hooper, D. C., Roy, A., Barkhouse, D. A., Li, J. & Kean, R. B. Rabies virus clearance from the central nervous system. Adv. Virus Res. 79, 55\u201371 (2011).","journal-title":"Adv. Virus Res."},{"key":"1030_CR45","first-page":"491","volume":"76","author":"J Lang","year":"1998","unstructured":"Lang, J., Simanjuntak, G. H., Soerjosembodo, S. & Koesharyono, C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull. World Health Organ. 76, 491\u2013495 (1998).","journal-title":"Bull. World Health Organ."},{"key":"1030_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/eji.202149766","volume":"52","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur. J. Immunol. 52, 753\u2013759 (2022).","journal-title":"Eur. J. Immunol."},{"key":"1030_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.06.026","volume":"162","author":"TT Wang","year":"2015","unstructured":"Wang, T. T. et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162, 160\u2013169 (2015).","journal-title":"Cell"},{"key":"1030_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/B978-0-12-387040-7.00003-2","volume":"79","author":"M Lafon","year":"2011","unstructured":"Lafon, M. Evasive strategies in rabies virus infection. Adv. Virus Res. 79, 33\u201353 (2011).","journal-title":"Adv. Virus Res."},{"key":"1030_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-419","volume":"2","author":"K Senba","year":"2013","unstructured":"Senba, K. et al. Passive carriage of rabies virus by dendritic cells. SpringerPlus 2, 419 (2013).","journal-title":"SpringerPlus"},{"key":"1030_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1471-4906(01)02007-5","volume":"22","author":"ED Carosella","year":"2001","unstructured":"Carosella, E. D., Moreau, P., Aractingi, S. & Rouas-Freiss, N. HLA-G: a shield against inflammatory aggression. Trends Immunol. 22, 553\u2013555 (2001).","journal-title":"Trends Immunol."},{"key":"1030_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.humimm.2006.12.003","volume":"68","author":"F M\u00e9gret","year":"2007","unstructured":"M\u00e9gret, F. et al. Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. Hum. Immunol. 68, 294\u2013302 (2007).","journal-title":"Hum. Immunol."},{"key":"1030_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0264-410X(91)90241-W","volume":"9","author":"P Perrin","year":"1991","unstructured":"Perrin, P. et al. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees. Vaccine 9, 549\u2013558 (1991).","journal-title":"Vaccine"},{"key":"1030_CR53","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.3390\/ijms241713587","volume":"24","author":"H Zhao","year":"2023","unstructured":"Zhao, H. et al. Immune response of inactivated rabies vaccine inoculated via intraperitoneal, intramuscular, subcutaneous and needle-free injection technology-based intradermal routes in mice. Int. J. Mol. Sci. 24, 13587 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1030_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.166","volume":"3","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers. MedComm. 3, e166 (2022).","journal-title":"MedComm."},{"key":"1030_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103805","volume":"75","author":"G Moncunill","year":"2022","unstructured":"Moncunill, G. et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and na\u00efve healthcare workers. EBioMedicine 75, 103805 (2022).","journal-title":"EBioMedicine"},{"key":"1030_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","volume":"212","author":"F Cliquet","year":"1998","unstructured":"Cliquet, F., Aubert, M. & Sagn\u00e9, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212, 79\u201387 (1998).","journal-title":"J. Immunol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01030-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01030-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01030-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:07:52Z","timestamp":1732712872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01030-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01030-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}